Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420132 · ClinicalTrials.gov registry record
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 47
- Enrollment target
NCT02420132: Completed study, sponsored by Hoffmann-La Roche.
NCT02420132 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02420132 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab therapy. In the main, decentralized study, participants will be recruited via digital media, advocacy groups, or through their own ophthalmologist. The traditional substudy will evaluate the association between visual acuity and anatomical markers of disease status determined using clinical "gold standard" assessments (certified Early Treatment Diabetic Retinopathy Study \[ETDRS\] protocol visual acuity and macula optical coherence tomography \[OCT\]) and the results of home vision testing using the myVisionTrack\^TM (mVT) application.
Interventions
- OTHER Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-04-20 |
| Est. Completion | 2016-08-25 |
What the finished NCT02420132 record still lists
NCT02420132 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT02420132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02420132 about?
NCT02420132 is a clinical study titled "Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)". This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab therapy. In the main, decentralized study, participants will be recruited...
What is the current status of trial NCT02420132?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2015-04-20. Estimated completion is 2016-08-25.
What interventions are being tested in trial NCT02420132?
The interventions under investigation include: Ranibizumab (OTHER).
Who is sponsoring clinical trial NCT02420132?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI